Arbutus Biopharma Corporation
ABUS
$3.60
$0.0150.42%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.74M | 1.76M | 1.57M | 1.34M | 1.73M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.74M | 1.76M | 1.57M | 1.34M | 1.73M |
| Cost of Revenue | 374.00K | 8.96M | 8.81M | 14.27M | 1.12M |
| Gross Profit | 10.37M | -7.20M | -7.24M | -12.93M | 607.00K |
| SG&A Expenses | 3.33M | 5.83M | 8.43M | 4.54M | 7.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.83M | 14.79M | 17.24M | 18.81M | 23.10M |
| Operating Income | 1.91M | -13.03M | -15.67M | -17.47M | -21.37M |
| Income Before Tax | 2.52M | -24.53M | -12.53M | -19.72M | -19.80M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 2.52M | -24.53M | -12.53M | -19.72M | -19.80M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.52M | -24.53M | -12.53M | -19.72M | -19.80M |
| EBIT | 1.91M | -13.03M | -15.67M | -17.47M | -21.37M |
| EBITDA | 1.92M | -12.70M | -15.34M | -17.14M | -21.02M |
| EPS Basic | 0.01 | -0.13 | -0.07 | -0.10 | -0.11 |
| Normalized Basic EPS | 0.01 | -0.04 | -0.05 | -0.05 | -0.07 |
| EPS Diluted | 0.01 | -0.13 | -0.07 | -0.10 | -0.11 |
| Normalized Diluted EPS | 0.01 | -0.04 | -0.05 | -0.05 | -0.07 |
| Average Basic Shares Outstanding | 191.55M | 190.71M | 189.70M | 189.00M | 188.04M |
| Average Diluted Shares Outstanding | 192.40M | 190.71M | 189.70M | 189.00M | 188.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |